US RESEARCH ROUNDUP-Arxis, Cigna, Vylor

By Reuters News

Oct 2 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several US-listed companies, including Arxis, Cigna, and Vylor, on Friday.

HIGHLIGHTS

* Arxis, Inc. ARXS.O: RBC raises to outperform from sector perform

* Cigna CI.N: Piper Sandler raises target price to $370 from $346

* Vylor Inc. VYLR.N: RBC initiates coverage with outperform rating; price target $85

The following is a summary of research actions on US companies reported by Reuters on Friday. Stock entries are in alphabetical order.


* Allegro Microsystems Inc ALGM.O: RBC initiates coverage with outperform rating

* Allegro Microsystems Inc ALGM.O: RBC initiates coverage with target price $50

* Antero Resources Corporation AR.N: Jefferies cuts target price to $56 from $60

* Arxis, Inc. ARXS.O: RBC raises to outperform from sector perform

* Arxis, Inc. ARXS.O: RBC raises target price to $60 from $50

* Bank of America BAC.N: JP Morgan cuts target price to $62 from $68

* Bank of New York Mellon Corp BNY.N: JP Morgan raises target price to $161 from $159

* Bankunited, Inc. BKU.N: Piper Sandler cuts target price to $47 from $50

* Ceribell, Inc. CBLL.O: TD Cowen raises target price to $33 from $29

* Cigna CI.N: Piper Sandler raises target price to $370 from $346

* Citigroup C.N: JP Morgan cuts target price to $147 from $149

* Citizens Financial CFG.N: JP Morgan cuts target price to $72.5 from $78

* Crowdstrike CRWD.O: TD Cowen raises target price to $280 from $250

* Expand Energy Corporation EXE.O: Jefferies cuts target price to $136 from $143

* Fifth Third Bancorp FITB.N: JP Morgan cuts target price to $58 from $62

* Foghorn Therapeutics Inc. FHTX.O: BTIG cuts to Nutral from buy

* Foghorn Therapeutics Inc. FHTX.O: Guggenheim cuts target price to $5 from $12

* Foghorn Therapeutics Inc. FHTX.O: Jefferies cuts target price to $5 from $12

* Goodyear Tire & Rubber Co GT.O: JP Morgan cuts target price to $9 from $10

* Graham Corp GHM.N: JP Morgan initiates coverage with overweight rating; PT $120

* Hess Midstream LP HESM.N: JP Morgan cuts to underweight from neutral

* Huntington Bancshares Inc HBAN.O: JP Morgan cuts target price to $17.5 from $19.5

* Keycorp KEY.N: JP Morgan cuts target price to $23 from $24.5

* Levi Strauss & Co LEVI.N: Raymond James cuts target price to $24 from $27

* Ltc Properties, Inc. LTC.N: RBC raises target price to $52 from $45

* M&T Bank Corporation MTB.N: JP Morgan cuts target price to $248.5 from $265.5

* McCormick & Company, Incorporated MKC.N: Jefferies cuts target price to $59 from $62

* McCormick & Company, Incorporated MKC.N: JP Morgan cuts target price to $55 from $62

* Medallion Financial Corp MFIN.O: Piper Sandler raises target price to $12 from $10.5

* Nike, Inc. NKE.N: BTIG cuts target price to $50 from $55

* Nike, Inc. NKE.N: Jefferies cuts target price to $60 from $75

* Nike, Inc. NKE.N: Morgan Stanley cuts target price to $27 from $31

* Nike, Inc. NKE.N: Piper Sandler cuts target price to $28 from $38

* Northern Trust Corporation NTRS.O: JP Morgan cuts target price to $185 from $185.50

* Northrop Grumman NOC.N: RBC cuts to sector perform from outperform

* Northrop Grumman NOC.N: RBC cuts target price to $525 from $640

* Oge Energy Corp. OGE.N: Jefferies cuts target price to $52 from $60

* Onto Innovation Inc. ONTO.N: RBC initiates coverage with outperform rating

* Onto Innovation Inc. ONTO.N: RBC initiates coverage with target price $400

* Origin Bancorp Inc OBK.N: Raymond James raises target price to $58 from $56

* Palo Alto Networks, Inc. PANW.O: TD Cowen raises target price to $440 from $400

* Pepsico PEP.O: UBS cuts target price to $145 from $159

* Pfizer PFE.N: Jefferies raises target price to $35 from $34

* Pinnacle Financial Partners, Inc. PNFP.N: Piper Sandler raises PT to $125 from $123

* PNC Financial Services PNC.N: JP Morgan cuts target price to $258 from $269.5

* Praxis Precision Medicines, Inc. PRAX.O: Jonestrading raises PT to $534 from $441

* Regeneron Pharmaceuticals Inc. REGN.O: Jefferies raises target price to $930 from $870

* Regions Financial RF.N: JP Morgan cuts target price to $30.5 from $32

* RLI Corp RLI.N: Jefferies cuts target price to $47 from $53

* SEI Investments Company SEIC.O: Raymond James cuts target price to $121 from $124

* Sentinelone Inc S.N: TD Cowen raises target price to $29 from $26

* Servisfirst Bancshares Inc SFBS.N: Piper Sandler cuts target price to $46 from $47

* State Street Corporation STT.N: JP Morgan raises target price to $187.50 from $187

* Suja Life Inc SUJA.O: Roth MKM initiates coverage with buy rating; price target $20

* Truist Financial Corporation TFC.N: JP Morgan cuts target price to $50.5 from $54

* U.S. Bancorp USB.N: JP Morgan cuts target price to $65 from $69

* Uranium Energy Corp. UEC.A: RBC initiates coverage with sector perform rating

* Uranium Energy Corp. UEC.A: RBC initiates coverage with price target $10

* Vylor Inc. VYLR.N: RBC initiates coverage with outperform rating; price target $85

* Wells Fargo WFC.N: JP Morgan cuts target price to $91.5 from $95.5

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.